Directory
Luis Brieva Ruiz

Luis Brieva Ruiz

Degree: PhD

973 705 367
lbrieva.lleida.ics(ELIMINAR)@gencat.cat

ResearcherID: http://www.researcherid.com/rid/C-3812-2011

Groups

Publications

  • Fernández O; Montalbán X; Agüera E; Aladro Y; Alonso A; Arroyo R; Brieva L; Calles C; Costa-Frossard L; Eichau S; García-Domínguez JM; Hernández MA; Landete L; Llaneza M; Llufriu S; Meca-Lallana JE; Meca-Lallana V; Moral E; Prieto JM; Ramió-Torrentà L; Téllez N; Romero-Pinel L; Vilaseca A; Rodríguez-Antigüedad A

    XVI Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2023 (II).

    REVISTA DE NEUROLOGIA 79 51-66. .

    [doi:10.33588/rn.7902.2024174]

  • Meca-Lallana JE; Martínez Yélamos S; Eichau S; Llaneza MÁ; Martín Martínez J; Peña Martínez J; Meca Lallana V; Alonso Torres AM; Moral Torres E; Río J; Calles C; Ares Luque A; Ramió-Torrentà L; Marzo Sola ME; Prieto JM; Martínez Ginés ML; Arroyo R; Otano Martínez MÁ; Brieva Ruiz L; Gómez Gutiérrez M; Rodríguez-Antigüedad Zarranz A; Sánchez-Seco VG; Costa-Frossard L; Hernández Pérez MÁ; Landete Pascual L; González Platas M; Oreja-Guevara C

    Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023.

    Neurologia (barcelona, Spain) 39 196-208. .

    [doi:10.1016/j.nrleng.2024.01.003]

  • González-Mingot C.; Gil-Sánchez A.; Begué-Gómez R.; López-Ortega R.; Luis B.R.

    Ischemic encephalopathic debut of CADASIL, a case report: It is better to be safe than sorry

    NEUROLOGIA -. .

    [doi:10.1016/j.nrl.2023.02.002]

  • Gil-Sánchez A.; Gonzalo H.; Canudes M.; Nogueras L.; González-Mingot C.; Valcheva P.; Torres P.; Serrano J.C.; Peralta S.; Solana M.J.; Brieva L.

    Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?

    PHARMACEUTICALS 17 -. .

    [doi:10.3390/ph17040459]

  • Sancho--Saldaña, A; Gil-Sánchez, A; González-Mingot, C; Peralta, S; Solana, MJ; Torres, P; Juanes, A; Quibus, L; Ruiz, E; Sanpedro, E; Quirant-Sánchez, B; Martínez-Cáceres, E; Tello, CR; Presas-Rodríguez, S; Rubio, SG; Baron, BP; Ramio-Torrenta, L; Sotoca, J; González-Suarez, I; Eichau, S; Prieto-Gonzalez, JM; Quilez, MRB; Sabin-Muñoz, J; Sánchez-López, AJ; Calatayud, GL; Calles, C; Sempere, AP; Garces, M; Carmona, O; Moral, E; Hervas, JV; Blanco, Y; Sola-Valls, N; Lara, NT; Forero, L; Brieva, L

    Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study

    Journal of Clinical Medicine 12 -. .

    [doi:10.3390/jcm12237243]

  • Brochet, B; Solari, A; Lechner-Scott, J; Piehl, F; Langdon, D; Hupperts, R; Selmaj, K; Patti, F; Brieva, L; Maida, EM; Alexandri, N; Smyk, A; Nolting, A; Keller, B; Montalban, X; Havrdova, EK

    Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study

    MULTIPLE SCLEROSIS JOURNAL 29 1808-1818. .

    [doi:10.1177/13524585231205962]

  • Mingot, CG; Lasaosa, SS; Campas, LC; Canaval, LC; Sánchez, AG; Ruiz, LB; Alonso, MCM; Moncusi, SP; Marsal, JV; Carner, SC; García, FP

    Prophylactic treatment can modify vascular risk biomarkers in high-frequency episodic and chronic migraine patients: a pilot study

    SCIENTIFIC REPORTS 13 19416-19416. .

    [doi:10.1038/s41598-023-44522-8]

  • Koch, MW; Moral, E; Brieva, L; Mostert, J; Strijbis, EM; Comtois, J; Repovic, P; Bowen, JD; Wolinsky, JS; Lublin, FD; Cutter, G

    Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset

    MULTIPLE SCLEROSIS JOURNAL 29 1776-1785. .

    [doi:10.1177/13524585231202320]

  • Fernández O; Montalban X; Agüera E; Aladro Y; Alonso A; Arroyo R; Brieva L; Calles C; Costa-Frossard L; Eichau S; García-Domínguez JM; Hernández MA; Landete L; Llaneza M; Llufriu S; Meca-Lallana JE; Meca-Lallana V; Mongay-Ochoa N; Moral E; Oreja-Guevara C; Ramió-Torrentà L; Téllez N; Romero-Pinel L; Rodríguez-Antigüedad A

    XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II).

    REVISTA DE NEUROLOGIA 77 47-60. .

    [doi:10.33588/rn.7702.2023168]

  • Fernández, O; Montalban, X; Agüera, E; Aladro, Y; Alonso, A; Arroyo, R; Brieva, L; Calles, C; Costa-Frossard, L; Eichau, S; García-Domínguez, JM; Hernández, MA; Landete, L; Llufriu, MLS; Meca-Lallana, JE; Meca-Lallana, V; Mongay-Ochoa, N; Moral, E; Oreja-Guevara, C; Ramió-Torrentà, L; Téllez, N; Romero-Pinel, L; Rodríguez-Antigüedad, A

    15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part I)

    REVISTA DE NEUROLOGIA 77 19-30. .

    [doi:10.33588/rn.7701.2023167]

  • González-Mingot, C; Miana-Mena, FJ; Iñarrea, PJ; Iñiguez, C; Capablo, JL; Osta, R; Gil-Sánchez, A; Brieva, L; Larrodé, P

    Mitochondrial Aconitase Enzymatic Activity: A Potential Long-Term Survival Biomarker in the Blood of ALS Patients

    Journal of Clinical Medicine 12 -. .

    [doi:10.3390/jcm12103560]

  • Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L

    A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.

    JOURNAL OF NEUROLOGY 270 1-12. .

    [doi:10.1007/s00415-023-11575-8]

Projects

  • EMCOVID-19: Esclerosis Múltiple y COVID-19
  • "Registro de pacientes con esclerosis múltiple (EM) tratados con Natalizumab en España"
  • UTILIDAD DE LA REALIZACION DE SECUENCIAS DE DIFUSION Y LA DETERMINACION DE BIOMARCADORES EN EL PRONOSTICO DE LOS PACIENTES CON UN ATAQUE ISQUEMICO TRANSITORIO